The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation

Clin Exp Immunol. 2020 Jul;201(1):34-39. doi: 10.1111/cei.13419. Epub 2020 Feb 17.

Abstract

Systemic sclerosis (SSc) is a complex, heterogeneous autoimmune connective tissue disease. Autologous hematopoietic stem-cell transplantation (AHSCT) has emerged as a valuable treatment option for rapidly progressive diffuse cutaneous SSc (dcSSc) patients, and thus far is the only treatment that has been shown to have a long-term clinical benefit. AHSCT is thought to reintroduce immune homeostasis through elimination of pathogenic self-reactive immune cells and reconstitution of a new, tolerant immune system. However, the mechanism of action underlying this reset to tolerance remains largely unknown. In this study we review the immune mechanisms underlying AHSCT for SSc, with a focus on the role of the innate immune cells, including monocytes and natural killer (NK) cells, in restoring immune balance after AHSCT.

Keywords: autologous hematopoietic stem-cell transplantation; diffuse cutaneous systemic sclerosis; immunological tolerance; innate immunity.

Publication types

  • Review

MeSH terms

  • Autografts
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunity, Innate*
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / pathology
  • Monocytes / immunology*
  • Monocytes / pathology
  • Scleroderma, Systemic / immunology*
  • Scleroderma, Systemic / pathology
  • Scleroderma, Systemic / therapy*